Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

[1]  P. Petersen,et al.  Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation , 2003 .

[2]  C. Granger,et al.  Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. , 2003, European heart journal.

[3]  Ulf Bredberg,et al.  Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects , 2003, European Journal of Clinical Pharmacology.

[4]  U. Bredberg,et al.  Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[5]  S. Schulman,et al.  A randomized, controlled, dose‐guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I , 2003, Journal of thrombosis and haemostasis : JTH.

[6]  L. Johansson,et al.  Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor , 2003, Clinical pharmacokinetics.

[7]  U. Eriksson,et al.  No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran , 2003, Clinical pharmacokinetics.

[8]  L. Johansson,et al.  No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers , 2003, Clinical pharmacokinetics.

[9]  P. Petersen,et al.  Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. , 2003, Journal of the American College of Cardiology.

[10]  E. Falk,et al.  Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. , 2003, European heart journal.

[11]  G. Specchia,et al.  Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2002, European heart journal.

[12]  B. Eriksson,et al.  Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial , 2002, The Lancet.

[13]  Carl J Pepine,et al.  ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.

[14]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[15]  H. Arnesen,et al.  Warfarin, aspirin, or both after myocardial infarction. , 2002, The New England journal of medicine.

[16]  D. Grobbee,et al.  Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial , 2002, The Lancet.

[17]  M. Wolzt,et al.  Inhibition of Thrombin Generation by the Oral Direct Thrombin Inhibitor Ximelagatran in Shed Blood from Healthy Male Subjects , 2002, Thrombosis and Haemostasis.

[18]  R. Califf,et al.  Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data , 2002, The Lancet.

[19]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[20]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[21]  Assent investigators.  Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction , 2001, The Lancet.

[22]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[23]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[24]  Hugo A. Katus,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, European heart journal.

[25]  E. Antman,et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.

[26]  L. Wallentin,et al.  Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999, The Lancet.

[27]  A. Siegbahn,et al.  Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. , 1999, Lancet.

[28]  R. Jay.  Low-molecular-weight heparin during instability in coronary artery disease , 1996, The Lancet.

[29]  J. Cairns,et al.  Antithrombotic agents in coronary artery disease. , 1995, Chest.

[30]  D. Waters,et al.  Reactivation of unstable angina after the discontinuation of heparin. , 1992, The New England journal of medicine.